- Home
- TCRT vs EYEN Comparison
TCRT vs EYEN Comparison
Compare TCRT & EYEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRT
- EYEN
- Stock Information
- Founded
- TCRT 1998
- EYEN 2014
- Country
- TCRT United States
- EYEN United States
- Employees
- TCRT N/A
- EYEN N/A
- Industry
- TCRT Biotechnology: Pharmaceutical Preparations
- EYEN Biotechnology: Pharmaceutical Preparations
- Sector
- TCRT Health Care
- EYEN Health Care
- Exchange
- TCRT Nasdaq
- EYEN Nasdaq
- Market Cap
- TCRT 2.5M
- EYEN 2.0M
- IPO Year
- TCRT N/A
- EYEN 2018
- Fundamental
- Price
- TCRT $2.63
- EYEN $1.09
- Analyst Decision
- TCRT
- EYEN Hold
- Analyst Count
- TCRT 0
- EYEN 4
- Target Price
- TCRT N/A
- EYEN $2.00
- AVG Volume (30 Days)
- TCRT 1.5M
- EYEN 45.2K
- Earning Date
- TCRT 05-14-2025
- EYEN 04-15-2025
- Dividend Yield
- TCRT N/A
- EYEN N/A
- EPS Growth
- TCRT N/A
- EYEN N/A
- EPS
- TCRT N/A
- EYEN N/A
- Revenue
- TCRT $10,000.00
- EYEN $57,336.00
- Revenue This Year
- TCRT $5,680,500.00
- EYEN $7,680.45
- Revenue Next Year
- TCRT N/A
- EYEN $315.38
- P/E Ratio
- TCRT N/A
- EYEN N/A
- Revenue Growth
- TCRT 100.00
- EYEN 1414.02
- 52 Week Low
- TCRT $1.31
- EYEN $0.85
- 52 Week High
- TCRT $14.20
- EYEN $124.80
- Technical
- Relative Strength Index (RSI)
- TCRT 54.55
- EYEN 39.27
- Support Level
- TCRT $2.27
- EYEN $1.02
- Resistance Level
- TCRT $2.93
- EYEN $1.18
- Average True Range (ATR)
- TCRT 0.40
- EYEN 0.09
- MACD
- TCRT -0.05
- EYEN 0.06
- Stochastic Oscillator
- TCRT 33.04
- EYEN 72.73
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.